{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:51:29Z","timestamp":1790175089616,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.amjcard.2007.08.011","type":"journal-article","created":{"date-parts":[[2007,11,29]],"date-time":"2007-11-29T18:09:20Z","timestamp":1196359760000},"page":"S32-S40","source":"Crossref","is-referenced-by-count":58,"special_numbering":"S1","title":["High-Density Lipoprotein Metabolism: Potential Therapeutic Targets"],"prefix":"10.1016","volume":"100","author":[{"given":"Michael H.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2007.08.011_bib1","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","article-title":"Heart Disease and Stroke Statistics\u20142007 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"115","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.08.011_bib2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update, endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.08.011_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.08.011_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2007.02.004","article-title":"Should both HDL-C and LDL-C be targets for lipid therapy?","volume":"1","author":"Brown","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib5","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.08.011_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199108083250601","article-title":"A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction","volume":"325","author":"Stampfer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.08.011_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.ATV.17.1.107","article-title":"Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8,000 men","volume":"17","author":"Goldbourt","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl A","key":"10.1016\/j.amjcard.2007.08.011_bib8","first-page":"A2","article-title":"The M\u00fcnster Heart Study (PROCAM), results of follow-up at 8 years","volume":"19","author":"Assman","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2007.08.011_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.08.011_bib10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","article-title":"New insights into the regulation of HDL metabolism and reverse cholesterol transport","volume":"96","author":"Lewis","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2007.08.011_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11883-003-0010-5","article-title":"Reverse cholesterol transport: high-density lipoprotein\u2019s magnificent mile","volume":"5","author":"Toth","year":"2003","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2007.08.011_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02693933","article-title":"Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol","volume":"9","author":"Toth","year":"2007","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2007.08.011_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2217\/17460875.2.3.285","article-title":"Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport","volume":"3","author":"Robinson","year":"2007","journal-title":"Future Lipidol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib14","series-title":"Comprehensive Management of High Risk Cardiovascular Patients","first-page":"295","article-title":"High-density lipoprotein cholesterol","author":"Toth","year":"2006"},{"key":"10.1016\/j.amjcard.2007.08.011_bib15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1172\/JCI0216500","article-title":"Intracellular cholesterol transport","volume":"110","author":"Maxfield","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2007.08.011_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/17460875.2.3.277","article-title":"Torcetrapib and atherosclerosis: what happened and where do we go from here?","volume":"2","author":"Toth","year":"2007","journal-title":"Future Lipidol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.ATV.0000057572.97137.DD","article-title":"Importance of different pathways of cellular cholesterol efflux","volume":"23","author":"Yancey","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/11905","article-title":"Mutations in ABCA1 in Tangier disease and familial high-density lipoprotein deficiency","volume":"22","author":"Brooks-Wilson","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjcard.2007.08.011_bib19","doi-asserted-by":"crossref","first-page":"9774","DOI":"10.1073\/pnas.0403506101","article-title":"ATP-binding cassette transporter G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins","volume":"101","author":"Wang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjcard.2007.08.011_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev.biochem.68.1.523","article-title":"Charting the fate of the \u201cgood cholesterol\u201d: identification and characterization of the high-density lipoprotein receptor SR-BI","volume":"68","author":"Krieger","year":"1999","journal-title":"Ann Rev Biochem"},{"key":"10.1016\/j.amjcard.2007.08.011_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/01.hco.0000126583.35391.eb","article-title":"Therapeutic interventions targeted at the augmentation of reverse cholesterol transport","volume":"19","author":"Toth","year":"2004","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib22","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.08.011_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for secondary prevention of coronary heart disease in men with low HDL-cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.08.011_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2007.08.011_bib25","doi-asserted-by":"crossref","first-page":"50K","DOI":"10.1016\/j.amjcard.2005.08.008","article-title":"High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies","volume":"96","author":"Toth","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.08.011_bib27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: result of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.08.011_bib28","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.08.011_bib29","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib30","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of rosuvastatin 10 to 40 milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib31","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1172\/JCI10852","article-title":"Statin-induced inhibition of the Rho-signaling pathway activates PPAR-\u03b1 and induces HDL apoA-I","volume":"107","author":"Martin","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2007.08.011_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11883-006-0063-3","article-title":"The effects of statins on high-density lipoproteins","volume":"8","author":"Schaefer","year":"2006","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2007.08.011_bib33","series-title":"The Mobile Lipid Clinic","author":"Davidson","year":"2005"},{"key":"10.1016\/j.amjcard.2007.08.011_bib34","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/01.CIR.0000126889.97626.B8","article-title":"High-density lipoprotein and cardiovascular risk","volume":"109","author":"Toth","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.08.011_bib35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079904125004402","article-title":"Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk, the role of nicotinic acid\u2014a position paper developed by the European Consensus Panel on HDL-C","volume":"20","author":"Chapman","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2007.08.011_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0002-9149(02)02436-0","article-title":"The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations","volume":"90","author":"Sacks","year":"2002","journal-title":"Am J Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2007.08.011_bib37","first-page":"S68","article-title":"Dyslipidemia management in adults with diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2007.08.011_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.amjcard.2007.08.011_bib40","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1074\/jbc.M210695200","article-title":"Molecular identification of high and low affinity receptors for nicotinic acid","volume":"278","author":"Wise","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2007.08.011_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0002-9149(02)03384-2","article-title":"Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism","volume":"91","author":"Rader","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib42","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2, a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2007.08.011_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003495-199000401-00004","article-title":"HDL-cholesterol as a risk factor in coronary heart disease: an update of the Helsinki Heart Study","volume":"40","author":"Frick","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.amjcard.2007.08.011_bib44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.33549\/physiolres.930081","article-title":"Cholesterol lowering and the vessel wall: new insights and future perspectives","volume":"50","author":"Stulc","year":"2001","journal-title":"Physiol Res"},{"key":"10.1016\/j.amjcard.2007.08.011_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.1988.03410050061031","article-title":"Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study","volume":"260","author":"Manninen","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.08.011_bib46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.amjcard.2005.09.078","article-title":"Relation between on treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial)","volume":"97","author":"Goldenberg","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","article-title":"Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease","volume":"47","author":"Barter","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib48","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.08.011_bib49","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.08.011_bib50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.08.011_bib51","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1161\/01.ATV.0000165694.39518.95","article-title":"Apolipoprotein A-I mimetic peptides","volume":"25","author":"Navab","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2007.08.011_bib52","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes, a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.08.011_bib53","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","article-title":"High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.08.011_bib54","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/01.RES.0000018422.31717.EE","article-title":"Recombinant apolipoprotein A-I Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks","volume":"90","author":"Chiesa","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2007.08.011_bib55","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914907016268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914907016268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T01:00:28Z","timestamp":1737594028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914907016268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0002914907016268"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2007.08.011","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}